Connect with us

Press Release

CMS: Initial Prescriptions for Silevimig Injection, the World’s First Bispecific Antibody Against Rabies, Issued in China

Published

2 months ago

on

SHENZHEN, CHINA – On 9 September, China Medical System Holdings Limited (867.HK/8A8.SG) (“CMS” or the “Group”) is pleased to announce that the initial prescriptions for the Class 1 innovative drug Silevimig Injection (the “Product”) have recently been issued in multiple hospitals across China, including Beijing Luhe Hospital of Capital Medical University, Wenzhou People’s Hospital, Kaiping Central Hospital, Dongguan Guangji Hospital and Huidong Jilong Ankang Hospital. This marks that the world’s first bispecific antibody for passive immunization against rabies has officially commenced its large-scale clinical application, offering a better solution for urgent post-exposure management against rabies in China.

 

Dual-Epitope Neutralization with Low Dosing, Addressing Clinical Pain Points

Silevimig Injection is the world’s first fully human bispecific antibody targeting dual epitopes (G protein epitopes I and III) of the rabies virus, which is consistent with the World Health Organization (“WHO”) recommendation for a “cocktail” therapeutic paradigm. It can effectively neutralize different viral strains or genotypes of the rabies virus, providing immediate protection before the establishment of full protection by active rabies vaccination, and building a critical line of defense against viral infection.

 

The Product is currently the passive immunization product with the smallest dose for rabies (0.05 mg/kg); compared with human rabies immune globulin (“HRIG”), it requires less injection volume and easier administration, which can effectively reduce pain and improve compliance for patient. Manufactured using recombinant technology, the Product is non-plasma-derived and carries no risk of blood-borne infections. It can be manufactured at scale through standardized and stable processes, with controllable production costs, while offering a single active ingredient, consistent quality and minimal batch-to-batch variability. These advantages open up new possibilities for improving the safety, standardized supply and patient accessibility of rabies passive immunization products, with the potential to further increase market penetration.

 

Initial Prescriptions Issued Within About Two Months After Approval, Academic-Driven Commercialization Platform Accelerating Value Realization

Silevimig Injection was approved for marketing in China in June 2026. Following the approval, CMS worked closely with its partner Genrix Bio to advance critical workstreams including drug supply, market access and academic promotion, while integrating expert networks and market resources. The inital prescriptions were issued in China within approximately two months, accelerating the translation of innovation outcomes into a clinically accessible new treatment option.

 

Currently, CMS has nine commercialized innovative drugs that are progressively achieving large-scale clinical application across China, accelerating the realization of the clinical value of each quality medicine. Going forward, CMS will remain focused on clinical unmet needs and continue to build a differentiated innovative product portfolio through a dual-track system of in-house R&D and collaborative R&D, accelerating accessibility of quality innovative drugs and taking concrete action to safeguard patients’ lives and health.

 

About Rabies

Rabies is an acute zoonotic disease caused by RABV, clinically characterized by aerophobia, hydrophobia, pharyngeal muscle spasms and progressive paralysis[1], with a case-fatality rate approaching 100%. At present, there is no proven treatment for rabies once clinical symptoms appear. Standardized post-exposure management, comprising wound care, vaccination and passive immunization administered as needed, remains the most effective strategy[2]. As vaccine-induced antibodies require 1-2 weeks after the first dose of vaccine injection to reach protective levels, passive immunization provides immediate coverage [1].

 

According to the National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition), patients with Category III exposure, patients with confirmed Category II exposure involving severe immunodeficiency, and patients with Category II exposure involving wounds to the head or face while the health status of the offending animal cannot be determined should receive passive immunization at the same time as the first dose of rabies vaccine[3]. In China, more than 40 million people are exposed to rabies annually, of whom approximately 40% fall under Category III exposure[1]. However, due to factors such as limited awareness, high price, and restricted accessibility, only about 15% of Category III cases receive passive immunization[1]. Currently, the primary passive immunization option in China is HRIG. However, HRIG must be sourced from healthy donors, making it difficult and costly to obtain. Furthermore, it carries potential risks of blood-borne infections. This has led to a low penetration rate of passive immunization products in China.

 

More Information about Silevimig Injection

In a Phase III clinical trial in adults in China, Silevimig Injection met its primary efficacy endpoint, demonstrating non-inferior protective efficacy compared with HRIG, the currently most used passive immunization product in China. The Product provides immediate protection during the early stages of rabies virus exposure without compromising the active immune response induced by vaccination. In addition, a Phase III clinical trial in children and adolescents aged 2 to <18 years is currently ongoing in China. The Product has been granted a patent in China.

 

In September 2025, the Group through subsidiaries of the Company entered into an Exclusive Collaboration Agreement (the “Agreement”) with Chongqing Genrix Biopharmaceutical Co., Ltd. In accordance with the Agreement, the Group has obtained exclusive commercialization rights for the Product in mainland China and exclusive licensing rights for the rest of the Asia-Pacific region, the Middle East and North Africa. The collaboration term extends until ten years after the Product receives the marketing approval in Mainland China (the “Initial Term for the Product”). Unless terminated or dissolved under the terms set forth in the Agreement, the Agreement will automatically renew for successive ten-year periods upon expiration of the Initial Term for the Product.

 

About CMS

CMS is an innovative pharmaceutical company focused on the identification, building, and full lifecycle management of differentiated specialty pharmaceuticals. With a dual-engine approach of in-house R&D and collaborative R&D, and leveraging its core capability to build markets and brands from the ground up, the Group enables each medicine to fully realize both its clinical value and commercial value.

 

CMS has established an end-to-end capability loop across the full product lifecycle—precisely identifying quality innovation targets, matching them with optimal development pathways, and efficiently advancing clinical development and registration; developing medical strategies aligned with clinical needs, and driving scaled clinical adoption through a professional academic promotion system and network.

 

CMS focuses on advantaged specialties including cardiovascular-kidney-metabolic, central nervous system, gastroenterology, ophthalmology, and skin health. Through professional academic promotion and academic resources across multiple disease areas, CMS has built sustainable scale advantages in specialties, with its skin health business becoming a leading player in its segment. Meanwhile, CMS continues to strengthen its international replication capabilities, validating the transferability of its business model in emerging markets such as Southeast Asia and the Middle East, and injecting long-term momentum for the Group’s high-quality, sustainable development.

 

Reference:

1. Chinese Center for Disease Control and Prevention. Technical Guidelines for Human Rabies Prevention and Control (2016). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P02024090652542…

2. Yin Wenwu, Wang Chuanlin, et al. Expert consensus on rabies exposure prophylaxis [J]. Chinese Journal of Preventive Medicine, 2019, 53(7): 668–679. DOI: 10.3760/cma.j.issn.0253-9624.2019.07.004

3. Chinese Center for Disease Control and Prevention. National Technical Guidelines for the Rabies Exposure Prophylaxis (2023 Edition). https://www.chinacdc.cn/jkyj/crb2/yl/kqb/jswj_kqb/202409/P020240906525421817465.pdf

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Widgets & Web Launches AI-Operated Investor Relations Websites for Public Companies at a Fixed $299 per Month

Published

2 days ago

on

October 24, 2026

By

Miami, Florida, United States, October 24th, 2026, FinanceWire

Widgets & Web, the investor relations website provider trusted by more than 500 public companies, SPACs, and IPO-stage firms, today announced AI-operated investor relations websites: complete, custom IR sites designed, built and maintained through AI-driven operations, at a single fixed price of $299 per month, billed annually at $3,588. The company says its operations run entirely on AI with zero employees, an operating model it describes as a first for the investor relations website industry.

Every site includes live stock price data, automated SEC filings from EDGAR, press release feeds, investor email alerts, corporate governance pages, and presentations and events sections. Sites are built for ADA and WCAG compliance, with an accessibility widget on every page. The subscription covers design, hosting, security monitoring, and unlimited updates and support, with no setup fees, no design fees, and no per-change charges.

Every site is built, hosted, maintained and controlled on Widgets & Web’s own proprietary platform: no WordPress, PHP, third-party content management systems or plugin dependencies to maintain. The company says this removes the upkeep and plugin maintenance that come with third-party platforms.

“Public companies have spent decades paying agency retainers and five-figure design bills for websites their investors visit for one thing: accurate, current information,” said Steve Yakubov, CEO and co-founder of Widgets & Web. “We build the entire IR site, keep every feed live around the clock, and deliver it at a price any issuer can approve in one meeting.”

Widgets & Web delivers the first draft of a new IR website within 24 hours of sign-up. Each IR site runs on a dedicated subdomain managed by Widgets & Web.

About Widgets & Web

Widgets & Web is a Miami-based investor relations website provider for public companies, SPACs and IPO-stage firms. The company designs, hosts and manages IR websites on its own proprietary platform, with automated SEC filing and press release feeds, live stock data, governance pages and investor email alerts, and has served more than 500 public companies. Learn more at www.widgetsandweb.com.

Contact

CEO and co-founder
Steve Yakubov
Widgets & Web
production@ir365connect.com
786-263-9007

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Thomas Berkley and Nexus Acquisition Group Outline AI Agency Partnership Approach in Cleveland

Published

2 days ago

on

October 24, 2026

By

United States, 24th Oct 2026— Thomas Berkley, founder of Nexus Acquisition Group, is advancing a partnership-focused approach to developing and operating artificial intelligence-powered agency businesses. Based in Cleveland, Ohio, the company works with a limited number of individuals, combining business-specific assessment, infrastructure development, and ongoing operations to establish AI-powered agency businesses.

As artificial intelligence becomes increasingly integrated into business operations, entrepreneurs are exploring ways to build companies around technology-enabled services. Nexus Acquisition Group addresses this opportunity through a model that extends beyond standalone software or technology implementation, with the company working directly alongside partners throughout the development and operation of their businesses.

The company’s approach centers on three stages: assess, build, and operate. Each engagement begins with evaluating the systems required for a specific business, continues with developing the necessary infrastructure, and extends into ongoing operations alongside the partner. This framework provides a defined process for individuals interested in building an agency business around AI-powered capabilities.

Thomas Berkley Leads Nexus Acquisition Group’s Partnership Model

Thomas Berkley founded Nexus Acquisition Group with a focus on building and operating AI-powered agency businesses through direct collaboration with partners. His background includes service in the United States Air Force and experience with AI-driven business systems and agency operations.

Berkley’s involvement is a central part of the company’s model. Rather than limiting its role to an initial consultation or infrastructure setup, Nexus Acquisition Group works with partners throughout the engagement. This continued involvement connects business planning, system development, and operational execution within a single working relationship.

For entrepreneurs evaluating Nexus Acquisition Cleveland, the company’s Cleveland base and its defined partnership process provide a starting point for understanding how engagements are structured. The company works with partners across the United States, with individual arrangements determined by the requirements of each business.

Nexus Acquisition AI Agency Program Follows a Three-Stage Framework

The Nexus Acquisition AI agency program is structured around assessing business requirements, building operational infrastructure, and supporting ongoing business activity. The process is designed to account for the specific needs of each agency rather than applying an identical technical setup to every engagement.

During the assessment stage, the company evaluates the systems needed to support the proposed business. This step helps establish the operational requirements and identify the infrastructure necessary for the agency’s intended activities.

The build stage focuses on developing that infrastructure. Depending on the requirements of the business, relevant systems may include AI-driven voice and messaging tools, customer relationship management platforms, and client acquisition systems. The objective is to establish the operational foundation needed to run the agency.

The third stage involves ongoing operation. Nexus Acquisition Group continues working with the partner after the initial infrastructure has been developed, maintaining a collaborative relationship as the business operates. The scope and duration of this work depend on the individual engagement.

By connecting these stages, the company approaches agency development as an ongoing business process rather than a one-time technology installation.

A Collaborative Structure for AI Agency Development

Building an agency around artificial intelligence involves more than selecting tools. Business owners must also consider how technology fits into their workflows, how systems are maintained, and how day-to-day operations are organized. A coordinated approach can help bring these requirements into a more consistent operating framework.

Nexus Acquisition Group’s model places collaboration at the center of this process. Partners work directly with the company’s team from the initial build through ongoing operation, while the systems and engagement structure are tailored to the particular business.

This approach may be relevant to individuals exploring AI-powered agency ownership who prefer a working relationship that includes both infrastructure development and operational involvement. Rather than presenting its services solely as access to software, the company describes its role as building and operating agency businesses in partnership with a limited number of individuals.

The model also recognizes that the requirements of an agency can differ according to its business objectives and operating needs. For this reason, engagements are structured individually, with the scope, terms, and timeline defined through an agreement between the company and the partner.

Nexus Acquisition Agency Partnership Opportunities

A Nexus Acquisition agency partnership provides a framework for discussing the development and operation of an AI-powered agency business. The company’s approach brings together assessment, implementation, and continuing operational involvement, allowing the parties to establish expectations before proceeding with an engagement.

For prospective partners, understanding the structure of the relationship is an important part of evaluating an opportunity. Nexus Acquisition Group outlines its process through its website, where interested individuals can review the company’s approach, learn about its founder, and contact the team to discuss a potential engagement.

The company does not describe every partnership as having identical requirements. Instead, its process is designed to reflect the systems needed for the specific business and the responsibilities agreed upon by the parties.

As AI-enabled services continue to create new possibilities for business development, Nexus Acquisition Group remains focused on connecting technology infrastructure with practical agency operations. Led by Berkley, the company continues to build its approach around direct partner involvement and an ongoing operational relationship.

Individuals interested in learning more about the company’s model can visit Nexus Acquisition Group to review its process and inquire about potential partnership opportunities.

About Nexus Acquisition Group

Nexus Acquisition Group is a Cleveland, Ohio-based company that builds and operates AI-powered agency businesses in partnership with a limited number of individuals. Founded by Thomas Berkley, the company follows an assess, build, and operate framework, working directly with partners from initial infrastructure development through ongoing operations. Its engagements are individually structured according to business requirements, scope, terms, and timeline.

Media Contact

Organization: Nexus Acquisition Group

Contact Person: Thomas Berkley

Website: https://nexusacquisitiongroup.com/

Email: Send Email

Address: Cleveland, Ohio, United States

Country: United States

Release id: 50182

View source version on King Newswire:
Thomas Berkley and Nexus Acquisition Group Outline AI Agency Partnership Approach in Cleveland

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Thomas Berkley of Nexus Acquisition AI Focuses on Turning Business Inquiries Into Structured Growth Opportunities

Published

2 days ago

on

October 24, 2026

By

United States, 24th Oct 2026 — Thomas Berkley of Nexus Acquisition AI is bringing attention to a critical challenge facing service businesses: creating a more organized path from initial customer interest to meaningful sales opportunities. As companies navigate changing customer expectations and increasingly competitive markets, the relationship between marketing, lead management, and business development is becoming an important consideration for long-term growth.

For service providers, attracting potential customers does not always translate into new business. Inquiries can go unanswered, follow-up can become inconsistent, and opportunities can be overlooked when teams lack a clear process for managing prospective clients. These challenges have prompted growing interest in systems that connect customer acquisition activities with the operational workflows needed to support them.

Nexus Acquisition AI operates in this evolving space, focusing on the intersection of artificial intelligence, marketing, and customer acquisition. Its work reflects a broader shift toward examining how technology can help businesses establish more consistent processes for engaging prospects and managing opportunities.

Moving Beyond Lead Volume

Businesses often evaluate marketing performance through the number of inquiries or contacts generated. However, lead volume represents only one part of the customer acquisition process. The ability to respond promptly, maintain relevant communication, and manage opportunities through subsequent stages can also influence the effectiveness of a company’s marketing efforts.

For service businesses with limited administrative resources, coordinating these activities can be particularly challenging. Owners and employees frequently balance customer delivery, scheduling, sales conversations, and daily management responsibilities. Without clearly defined procedures, potential customers may encounter delays or inconsistent communication.

Through its focus on Nexus Acquisition marketing, the company addresses a business environment in which marketing performance is increasingly considered alongside the processes responsible for managing incoming opportunities.

This perspective encourages businesses to examine the complete customer journey rather than viewing advertising, outreach, and sales follow-up as separate functions. It also highlights the importance of identifying gaps between generating interest and taking the next appropriate action.

Exploring Practical Applications of Artificial Intelligence

Artificial intelligence is creating new possibilities for businesses seeking to organize repetitive tasks and improve the coordination of customer-facing processes. Depending on the tools selected and their implementation, AI-supported workflows may assist with inquiry classification, routine communications, information organization, and follow-up management.

For companies evaluating these capabilities, the central question is not simply whether AI can be introduced into an existing operation. It is whether a particular application addresses a genuine business need and fits the way the organization serves its customers.

Nexus Acquisition AI’s focus on technology-assisted growth aligns with this practical consideration. Businesses exploring automation must account for their existing systems, customer communication standards, staffing capacity, and the level of human oversight required for effective implementation.

Automation can support consistency, but it does not eliminate the need for sound business judgment. Service providers must still ensure that customer interactions remain relevant, information is handled appropriately, and important decisions receive the necessary attention.

Building More Consistent Lead Management Processes

The period between a customer’s initial inquiry and a purchasing decision can involve multiple interactions. Prospective customers may request information, compare providers, ask additional questions, or require time before deciding whether to proceed.

A structured lead management process gives businesses a framework for handling these different stages. It can establish how inquiries are recorded, who is responsible for responding, when follow-up should occur, and how the status of each opportunity is tracked.

Within this context, Nexus Acquisition lead generation relates to the broader challenge of developing a more coordinated approach to attracting and managing potential customers.

Generating new inquiries remains important, but businesses also benefit from understanding what happens after those inquiries arrive. Reviewing response times, follow-up consistency, conversion patterns, and the sources of qualified opportunities can help decision-makers identify areas for improvement.

These measures provide a more comprehensive basis for evaluating marketing activity than lead counts alone. They also allow businesses to consider operational adjustments before increasing spending on customer acquisition.

Aligning Growth Technology With Business Objectives

Every service business operates under different conditions. A company serving a local market may have different customer acquisition requirements from a provider operating across multiple cities or industries. Similarly, businesses with small teams may prioritize administrative efficiency, while larger organizations may focus on coordinating workflows across departments.

Consequently, growth technology must be evaluated against specific operational requirements rather than adopted solely because it is available.

The concept of Nexus Acquisition AI growth systems reflects the broader market interest in connecting marketing activities, customer information, and follow-up processes within a more coordinated operating framework.

A useful evaluation begins with identifying recurring problems, establishing measurable objectives, and determining which tasks may benefit from automation. Businesses can then assess whether the selected systems improve workflow consistency, reduce unnecessary manual effort, or provide clearer insight into customer acquisition performance.

This measured approach helps keep technology adoption connected to practical business priorities.

A Process-Oriented Perspective on Business Development

As artificial intelligence becomes more accessible, service businesses have additional options for reconsidering how they organize marketing and sales activities. The opportunity lies in identifying where technology can complement existing capabilities while preserving the personal communication and service quality that customers expect.

Thomas Berkley and Nexus Acquisition AI are positioned within this changing business landscape, where the discussion around growth increasingly includes not only attracting customers but also establishing processes for managing the opportunities that marketing creates.

For businesses reviewing their acquisition strategies, the emphasis on connected workflows offers a useful starting point: understand where prospects enter the process, determine what happens next, and evaluate whether each stage supports the organization’s broader objectives.

Further information about Nexus Acquisition AI and its approach to marketing and customer acquisition is available on the company’s website at https://nexusacquisitionai.com/ .

About Nexus Acquisition AI

Nexus Acquisition AI focuses on marketing, lead generation, and AI-powered growth systems for service businesses. The company operates within the business technology and customer acquisition sector, addressing the growing interest in using automation and structured workflows to support marketing operations and business development.

Learn more at https://nexusacquisitionai.com/.

Media Contact

Organization: Nexus Acquisition AI

Contact Person: Thomas Berkley

Website: https://nexusacquisitionai.com/

Email: Send Email

Country: United States

Release id: 50183

View source version on King Newswire:
Thomas Berkley of Nexus Acquisition AI Focuses on Turning Business Inquiries Into Structured Growth Opportunities

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us